Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients

McDonald, Susan B.; Renna, Maurizio; Spitznagel, Edward L.; Avidan, Michael S.; Hogue, Charles W.; Moon, Marc R.; Barzilai, Benico; Saleem, Rao; McDonald, James I.; Despotis, George J.

doi:10.1053/j.jvca.2004.11.002

Cited by 47 publications

(24 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[271][272][273] It is particularly effective when an ischemic cause of the arrhythmia can be documented (for instance, when it occurs with exercise). 275 Still, because CABG may not alleviate all the factors that predispose to ventricular arrhythmias, concomitant insertion of an implantable cardioverter-defibrillator is often warranted. 276 Similarly, continued inducibility or clinical recurrence of ventricular tachycardia after CABG usually requires an implantable cardioverter-defibrillator implantation.…”

Section: Emergencymentioning

confidence: 99%

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery

et al. 2011

View full text Add to dashboard Cite

Section: Emergencymentioning

confidence: 99%

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery

et al. 2011

View full text Add to dashboard Cite

“…The initial enthusiasm for LMWH in cardiac procedures has been tempered by increased hemorrhagic complication rates for LMWH compared to UFH [13]. LMWH use has also been limited in intracranial procedures and should be used with caution when patients have neuraxial anesthetics.…”

Section: Discussionmentioning

confidence: 99%

A caution regarding the use of low-molecular weight heparin in pediatric otogenic lateral sinus thrombosis

Shah

Jubelirer

Fish

et al. 2007

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

“…Although some have attempted "bridging" stent patients with antithrombin agents, there is no evidence of a benefit of warfarin (Table 1) or other antithrombins, and there is an increased risk of bleeding. 31 Similarly, there are no data to support the use of "bridging" glycoprotein IIb/IIIa agents.…”

Section: Grines Et Al Antiplatelet Therapy To Avoid Stent Thrombosismentioning

confidence: 99%

Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents

Grines¹,

Bonow²,

Casey³

et al. 2007

Circulation

828

View full text Add to dashboard Cite

Abstract-Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and healthcare providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction, and death. This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a drug-eluting stent and educating the patient and healthcare providers about hazards of premature discontinuation. It also recommends postponing elective surgery for 1 year, and if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high-risk patients with drug-eluting stents. (Circulation. 2007;115:813-818.)

show abstract

Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients

Cited by 47 publications

References 40 publications

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery

A caution regarding the use of low-molecular weight heparin in pediatric otogenic lateral sinus thrombosis

Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents

Contact Info

Product

Resources

About